252 related articles for article (PubMed ID: 15867493)
1. Nelfinavir and nevirapine side effects during pregnancy.
Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
[TBL] [Abstract][Full Text] [Related]
2. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Tempelman C; Timmermans S; Godfried MH; Dieleman JP; Boer K; van der Ende ME
Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2021-5. PubMed ID: 15553999
[TBL] [Abstract][Full Text] [Related]
3. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
Marazzi MC; Germano P; Liotta G; Guidotti G; Loureiro S; da Cruz Gomes A; Valls Blazquez MC; Narciso P; Perno CF; Mancinelli S; Palombi L
HIV Med; 2006 Jul; 7(5):338-44. PubMed ID: 16945080
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
[TBL] [Abstract][Full Text] [Related]
6. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
; Patel D; Cortina-Borja M; Thorne C; Newell ML
Clin Infect Dis; 2007 Jun; 44(12):1647-56. PubMed ID: 17516411
[TBL] [Abstract][Full Text] [Related]
7. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Hitti J; Frenkel LM; Stek AM; Nachman SA; Baker D; Gonzalez-Garcia A; Provisor A; Thorpe EM; Paul ME; Foca M; Gandia J; Huang S; Wei LJ; Stevens LM; Watts DH; McNamara J;
J Acquir Immune Defic Syndr; 2004 Jul; 36(3):772-6. PubMed ID: 15213559
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
9. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
10. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Dorenbaum A; Cunningham CK; Gelber RD; Culnane M; Mofenson L; Britto P; Rekacewicz C; Newell ML; Delfraissy JF; Cunningham-Schrader B; Mirochnick M; Sullivan JL;
JAMA; 2002 Jul; 288(2):189-98. PubMed ID: 12095383
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
12. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
[TBL] [Abstract][Full Text] [Related]
13. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
16. Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Edwards SG; Larbalestier N; Hay P; de Ruiter A; Welch J; Taylor GP; Easterbrook P
HIV Med; 2001 Apr; 2(2):89-91. PubMed ID: 11737384
[TBL] [Abstract][Full Text] [Related]
17. The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
Jensen-Fangel S; Thomsen HF; Larsen L; Black FT; Obel N
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):124-9. PubMed ID: 11404533
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study.
Lorenzi P; Spicher VM; Laubereau B; Hirschel B; Kind C; Rudin C; Irion O; Kaiser L
AIDS; 1998 Dec; 12(18):F241-7. PubMed ID: 9875571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]